Evidence map›Paper›PMID 33831607›Full record

SynthesisAgeing research reviews2021

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.

Konstantinos I Avgerinos, Luigi Ferrucci, Dimitrios Kapogiannis

Registry-linked trialOpen access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Ageing research reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072963 (Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow), which is not on this map. Cited by 129 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 15 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
PMID 36871874PMID 29687620PMID 30635783PMID 30760178PMID 30868154PMID 30917904PMID 30944040PMID 30984815PMID 31022213PMID 31189511PMID 31924562PMID 32296731other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 15 syntheses or guidelines pooled it, 234 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Aducanumab for the treatment of Alzheimer's disease: a systematic review.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Article
  18. Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  19. Observational
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Konstantinos I AvgerinosLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Luigi FerrucciLongitudinal Study Section, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Dimitrios KapogiannisLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA. Electronic address: kapogiannisd@mail.nih.gov.
National Institute on Aging · US

Funding

Studies in Dementia and Neurodegenerative DiseasesZIAAG000975 · NIA · NATIONAL INSTITUTE ON AGING · PI KAPOGIANNIS, DIMITRIOS · 2009 to 2025
$31.5M
Intramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA AG000975
6 · The paper itself

Abstract

objectiveTo investigate the effects of monoclonal antibodies against Aβ on cognition, function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging abnormalities (ARIA) and other adverse events, in Alzheimer's disease (AD).

methodsPubmed, Web of Science, ClinicalTrials.gov and gray literature were searched for phase III RCTs and random-effects meta-analyses were performed.

resultsSeventeen studies (12,585 patients) were included. Antibodies statistically improved the cognitive outcomes ADAS-Cog {SMD = -0.06 [95 % CI (-0.10; -0.02), I

conclusionsIn this meta-analysis of phase III trials in AD, we found that monoclonal antibodies against Aβ induced clinical improvements of small effect sizes, biomarker improvements of large effect sizes, and increases in risk for the hallmark adverse event, ARIA, by a large effect size, when all drugs were pooled together. Among individual drugs, Aducanumab produced the most favorable effects followed by Solanezumab. These findings provide moderate support for the continuous development of anti-Aβ monoclonal antibodies as a treatment for AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloidogenic ProteinsAntibodies, MonoclonalBiomarkersClinical Trials, Phase III as TopicCognitionHumansRandomized Controlled Trials as TopicAmyloid beta-PeptidesAmyloidogenic ProteinsAntibodies, MonoclonalBiomarkersAlzheimer’s diseaseAmyloid-betaMeta-analysisMonoclonal antibodies

Identifiers

PMID33831607
PMCPMC8161699
OpenAlexW3146410983

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.